Phase I/II Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Patients with Advanced Solid Tumors, including Pancreatic Cancer
The purpose of this phase I/II study is to evaluate the safety and feasibility of NUV-868 as a monotherapy and in combination with Olaparib and Enzalutamide in patients with advanced solid tumors, including pancreatic cancer.
Study ID: NUV-868-01
Trial Phase: Phase I/II
Trial Sponsor: Nuvation Bio Inc.
Therapies Used in This Trial: Olaparib, Enzalutamide, NUV-868